Laurantis Pharma and Ark Therapeutics Sign Manufacturing

Laurantis Pharma and Ark Therapeutics Sign Manufacturing Agreement
for Production of Lymfactin(TM) Investigational Treatment for Breast
Cancer-Associated Lymphedema 
LONDON and TURKU, FINLAND -- (Marketwire) -- 10/15/12 --  Ark
Therapeutics has been selected to manufacture and supply
Lymfactin(TM) to Laurantis Pharma under a conditional agreement
announced today by the Finland-based companies. The agreement is
subject to Laurantis receiving regulatory approval to commence its
phase I clinical trial. Specific terms of the agreement are not
disclosed. Lymfactin(TM) uses an adenoviral vector to deliver
vascular endothelial growth factor (VEGF-C) during transplantation of
lymph nodes in order to avoid lymphedema.  
The phase I clinical trial using Lymfactin(TM) to treat breast
cancer-associated lymphedema is targeted to begin in 2013, and will
recruit patients in the USA and Finland. Breast cancer-associated
lymphedema is the most common form of secondary lymphedema, occurring
in approximately 20% of breast cancer patients who undergo axillary
lymph node dissection. The incidence is even higher in those who also
receive radiotherapy, and this complication may even occur in those
who undergo a lymph node biopsy as part of treatment. No therapeutic
treatment currently exists to treat this disease. 
In the US, approximately 110,000 patients are living with breast
cancer-associated lymphedema, and nearly 15,000 new patients develop
the complication each year. The number of lymphedema patients in
Europe is estimated to be roughly the same as in the US. 
About Laurantis Pharma Oy
 Based in Turku, Finland, Laurantis is a
privately held clinical-stage biotechnology company with a broad
portfolio of first-in-class products based on two proprietary
technologies. The Company's pipeline includes proprietary and
patent-protected formulations and applications of cis-urocanic acid,
a locally acting anti-inflammatory and anti-proliferative agent for
the treatment of Atopic Dermatitis, Dry Eye, Interstitial Cystitis,
and Bladder Cancer. Laurantis is also developing Lymfactin(TM), a
vascular endothelial growth factor C (VEGF-C) in an adenoviral
vector, as a gene therapy product for the treatment of secondary
lymphedema.  
About Ark Therapeutics Group plc
 Ark Therapeutics Group plc is a
leading viral product focused contract development and manufacturing
services company with world-class viral research, development and GMP
manufacturing operations in Finland and the UK. Ark's business model
is to offer product development and GMP manufacturing contract
services for viral products, including the areas of viral mediated
gene therapy, oncolytic viral vaccines, live and attenuated viral
vaccines, viral vectored vaccines and virus like particles. Ark's
capabilities span from translational research through preclinical and
clinical product development, in addition to process and analytical
development, GMP manufacture and sterile filling from pre-clinical
through to commercial product supply. These capabilities have been
established through the development of Ark's own products through to
Marketing Authorisation Application registered with the European
Medicines Agency. Following a change in business strategy in 2011,
Ark is now building its business through contract development and
manufacturing services and is seeking external partners to advance
those products it previously had under development.  
Ark's shares were first listed on the London Stock Exchange in March
2004 (LSE: AKT). 
This announcement includes "forward-looking statements" which include
all statements other than statements of historical facts, including,
without limitation, those regarding the Group's financial position,
business strategy, plans and objectives of management for future
operations (including development plans and objectives relating to
the Group's products and services), and any statements preceded by,
followed by or that include forward-looking terminology such as the
words "targets", "believes", "estimates", "expects", "aims",
"intends", "will", "can", "may", "anticipates", "would", "should",
"could" or similar expressions or the negative thereof. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors beyond the Group's control
that could cause the actual results, performance or achievements of
the Group to be materially different from future results, performance
or achievements expressed or implied by such forward-looking
statements. Such forward-looking statements are based on numerous
assumptions regarding the Group's present and future business
strategies and the environment in which the Group will operate in the
future. Among the important factors that could cause the Group's
actual results, performance or achievements to differ materially from
those in forward-looking statements include those relating to Ark's
funding requirements, regulatory approvals, clinical trials, reliance
on third parties, intellectual property, key personnel and other
factors. These forward-looking statements speak only as at the date
of this announcement. The Group expressly disclaims any obligation or
undertaking to disseminate any updates or revisions to any
forward-looking statements contained in this announcement to reflect
any change in the Group's expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statements are based. As a result of these factors, readers are
cautioned not to rely on any forward-looking statement. 
For further information: 
Ark Therapeutics Group plc
Tel: +44 (0)20 7388 7722
Dr David Venables
CEO
Iain Ross
Chairman 
Laurantis Pharma Oy
David Sheon 
Tel: +1 202 422-6999 
FTI Consulting, Inc (for Ark Therapeutics)
Tel: +44 (0)20 7831 3113
Ben Atwell
Susan Stuart 
 
 
Press spacebar to pause and continue. Press esc to stop.